Mathai Mammen
CIK 1421050 · EVP, Pharm, R&D · last filed 2024-06-13
Mathai Mammen is an EVP, Pharm, R&D who has filed 64 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for TXG, was dated Jun 13, 2024. Across all open-market trades the lifetime net is −$4.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $25.2M across reported positions. 50 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
THRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
901 GATEWAY BLVD.
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TXG | Director | 180,259 | $72.96 | $13.15M | -$1.74M | 7 | 2024-06-13 |
| JNJ | EVP, Pharm, R&D | 45,300 | $266.30 | $12.06M | $0 | 2 | 2022-02-17 |
| Theravance Biopharma, Inc. (TBPH) Delisted | SVP, Research & Development | 288,111 | $17.03 | $4.91M | $0 | 10 | 2016-03-17 |
| Innoviva, Inc. (THRX) Delisted | SVP, Research & Early Clin Dev | 334,040 | $4.06 | $1.36M | -$2.96M | 44 | 2014-08-22 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-13 | TXG | Grant (A) | +8,649 | $0 | EDGAR |
| 2023-06-16 | TXG | Grant (A) | +1,865 | $0 | EDGAR |
| 2023-05-15 | TXG | Mixed | +167,000 | -$1.51M | EDGAR |
| 2023-05-11 | TXG | Notice (144) | −33,000 | -$1.79M | EDGAR |
| 2022-06-17 | TXG | Grant (A) | +2,120 | $0 | EDGAR |
| 2022-02-17 | JNJ | Mixed | +4,374 | -$558.4K | EDGAR |
| 2022-02-15 | JNJ | Mixed | +5,083 | -$394.3K | EDGAR |
| 2021-06-15 | TXG | Grant (A) | +625 | $0 | EDGAR |
| 2020-06-17 | TXG | Grant (A) | — | $0 | EDGAR |
| 2019-09-16 | TXG | Other (J) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.